There has never been a safe and effective treatment for Graves’ eye disease, also known as thyroid eye disease (TED), for the 1 million Americans with the condition. Anti-inflammatory medicines offer inconsistent benefits. Orbital decompression surgery helps give some patients a more natural appearance, but only after the disease has run its course.
But a clinical trial led by the University of Michigan Kellogg Eye Center offers hope for those with moderate to severe active TED. Patients had a significant reduction in symptoms after treatment with teprotumumab, a study drug the Food and Drug Administration designated a “breakthrough therapy.”